First, we evaluated the ability of ZAP exposure to protect against the OS-induced death of DJ-1-deficient human neuroblastoma cells in a dose-dependent manner by pretreating them with ZAP (0.1–80 μM) and measuring viability via MTT assays. The gene discussed is PARK7; the disease is neuroblastoma.